Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Trial Profile

Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Bosutinib (Primary) ; Pemetrexed (Primary)
  • Indications Bladder cancer; Cervical cancer; Malignant thymoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Thymoma; Urethral cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top